Telemetry Investments L.L.C. bought a new stake in Pacific Biosciences of California (NASDAQ:PACB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,000 shares of the biotechnology company’s stock, valued at approximately $148,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Prudential Financial Inc. raised its position in Pacific Biosciences of California by 21.8% in the fourth quarter. Prudential Financial Inc. now owns 12,402 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 2,220 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Pacific Biosciences of California by 37.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,580 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 2,628 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Pacific Biosciences of California in the fourth quarter worth $26,000. Hudock Capital Group LLC acquired a new position in shares of Pacific Biosciences of California in the fourth quarter worth $29,000. Finally, United Services Automobile Association grew its stake in shares of Pacific Biosciences of California by 27.2% in the fourth quarter. United Services Automobile Association now owns 21,655 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 4,634 shares in the last quarter. 67.70% of the stock is currently owned by institutional investors.

Shares of PACB stock opened at $7.36 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 4.90 and a quick ratio of 4.23. The firm has a market cap of $1.11 billion, a P/E ratio of -9.68 and a beta of 2.41. Pacific Biosciences of California has a 12 month low of $2.02 and a 12 month high of $7.84.

Pacific Biosciences of California (NASDAQ:PACB) last issued its earnings results on Monday, February 11th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The firm had revenue of $19.53 million for the quarter, compared to analyst estimates of $21.08 million. Pacific Biosciences of California had a negative return on equity of 94.50% and a negative net margin of 130.44%. On average, sell-side analysts anticipate that Pacific Biosciences of California will post -0.56 earnings per share for the current year.

Several equities analysts have commented on PACB shares. BidaskClub downgraded shares of Pacific Biosciences of California from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 28th. ValuEngine downgraded shares of Pacific Biosciences of California from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 2nd. Finally, Cowen downgraded shares of Pacific Biosciences of California from an “outperform” rating to a “market perform” rating in a research note on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $5.64.

In related news, CFO Susan K. Barnes sold 11,987 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $7.16, for a total transaction of $85,826.92. Following the completion of the transaction, the chief financial officer now owns 729,407 shares in the company, valued at $5,222,554.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP James Michael Phillips sold 7,231 shares of the business’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $7.17, for a total transaction of $51,846.27. Following the transaction, the senior vice president now owns 223,156 shares of the company’s stock, valued at approximately $1,600,028.52. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,486 shares of company stock valued at $283,261. Insiders own 13.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/03/16/telemetry-investments-l-l-c-buys-new-stake-in-pacific-biosciences-of-california-pacb.html.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Featured Article: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.